Pettyjohn Wood & White Inc. Has $487,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Pettyjohn Wood & White Inc. lowered its position in Amgen Inc. (NASDAQ:AMGNGet Rating) by 3.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,164 shares of the medical research company’s stock after selling 71 shares during the period. Pettyjohn Wood & White Inc.’s holdings in Amgen were worth $487,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. OLD Mission Capital LLC acquired a new position in Amgen during the third quarter valued at approximately $239,000. Morgan Stanley grew its holdings in Amgen by 0.8% during the second quarter. Morgan Stanley now owns 10,040,932 shares of the medical research company’s stock valued at $2,447,476,000 after purchasing an additional 80,922 shares during the last quarter. Wolff Wiese Magana LLC grew its holdings in Amgen by 15.4% during the third quarter. Wolff Wiese Magana LLC now owns 11,273 shares of the medical research company’s stock valued at $2,397,000 after purchasing an additional 1,505 shares during the last quarter. Atwood & Palmer Inc. grew its holdings in Amgen by 1.8% during the third quarter. Atwood & Palmer Inc. now owns 58,900 shares of the medical research company’s stock valued at $12,525,000 after purchasing an additional 1,056 shares during the last quarter. Finally, Keudell Morrison Wealth Management grew its holdings in Amgen by 12.5% during the third quarter. Keudell Morrison Wealth Management now owns 3,085 shares of the medical research company’s stock valued at $656,000 after purchasing an additional 343 shares during the last quarter. Hedge funds and other institutional investors own 74.53% of the company’s stock.

Shares of AMGN traded up $2.05 during trading hours on Tuesday, hitting $253.98. The stock had a trading volume of 42,100 shares, compared to its average volume of 3,137,528. The stock has a market capitalization of $135.57 billion, a price-to-earnings ratio of 24.69, a P/E/G ratio of 1.52 and a beta of 0.59. The company has a debt-to-equity ratio of 4.96, a current ratio of 1.59 and a quick ratio of 1.26. The company’s fifty day moving average is $235.32 and its two-hundred day moving average is $222.95. Amgen Inc. has a 52 week low of $198.64 and a 52 week high of $261.00.

Amgen (NASDAQ:AMGNGet Rating) last issued its quarterly earnings data on Monday, February 7th. The medical research company reported $4.36 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.14 by $0.22. The firm had revenue of $6.85 billion for the quarter, compared to analysts’ expectations of $6.87 billion. Amgen had a net margin of 22.68% and a return on equity of 120.59%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.81 earnings per share. Equities analysts predict that Amgen Inc. will post 17.6 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 8th. Investors of record on Tuesday, May 17th will be issued a dividend of $1.94 per share. The ex-dividend date of this dividend is Monday, May 16th. This represents a $7.76 dividend on an annualized basis and a yield of 3.06%. Amgen’s dividend payout ratio is 75.27%.

Several equities research analysts have recently weighed in on the company. Barclays increased their price objective on Amgen from $233.00 to $236.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 12th. Morgan Stanley reduced their price objective on Amgen from $238.00 to $237.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 12th. Jefferies Financial Group increased their price objective on Amgen from $266.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, February 9th. Bank of America cut Amgen from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $285.00 to $255.00 in a research report on Wednesday, January 5th. Finally, Royal Bank of Canada increased their price objective on Amgen from $216.00 to $218.00 and gave the company a “sector perform” rating in a research report on Tuesday, December 21st. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $235.24.

About Amgen (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.